Literature DB >> 3484780

Clinicopathologic aspects of E rosette negative T cell acute lymphocytic leukemia: a Pediatric Oncology Group study.

M J Borowitz, B L Dowell, J M Boyett, D J Pullen, W M Crist, F M Quddus, J M Falletta, R S Metzgar.   

Abstract

The Pediatric Oncology Group has studied 1,367 patients with non-B cell acute lymphocytic leukemia (ALL) of whom 186 (14%) had blasts that reacted with previously well-characterized heteroantisera, recognizing a T-lymphocyte specific surface membrane antigen (PT+). In 87 of these T cell cases, the leukemic cells failed to form at least 20% of sheep erythrocytic rosettes at 4 degrees C. Comparison of clinicopathologic features among PT-, E-PT+, and E+ groups of patients revealed significant differences among them. E-PT+ patients were older than PT- patients, had higher white blood cell counts (WBCs) and were more likely to have a mediastinal mass, and thus contained a higher proportion of poor-risk patients. However, the E-PT+ patients were also significantly different from the more traditionally-defined E+ patients in that they had lower WBCs and hemoglobin levels, and less frequent lymphadenopathy or mediastinal mass. In many respects, then, E-PT+ patients were intermediate in character between PT- and E+ patients. Our findings support the notion that further subclassification of ALL using antibodies recognizing lineage-specific surface determinants will permit recognition of groups of patients with distinct clinicopathologic features that may differ in prognosis or response to therapy. Such classification also focuses future biological studies on the pathogenesis of leukemias to immunologically well-defined subgroups of lymphoid neoplasms.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484780     DOI: 10.1200/JCO.1986.4.2.170

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  4 in total

1.  Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies.

Authors:  Yousif Matloub; Linda Stork; Barbara Asselin; Stephen P Hunger; Michael Borowitz; Tamekia Jones; Bruce Bostrom; Julie M Gastier-Foster; Nyla A Heerema; Andrew Carroll; Naomi Winick; William L Carroll; Bruce Camitta; Meenakshi Devidas; Paul S Gaynon
Journal:  Pediatr Blood Cancer       Date:  2015-10-20       Impact factor: 3.167

2.  Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.

Authors:  Stuart S Winter; Kimberly P Dunsmore; Meenakshi Devidas; Nancy Eisenberg; Barbara L Asselin; Brent L Wood; Marcia S Leonard Rn; John Murphy; Julie M Gastier-Foster; Andrew J Carroll; Nyla A Heerema; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; William L Carroll; Stephen P Hunger
Journal:  Pediatr Blood Cancer       Date:  2015-03-08       Impact factor: 3.167

3.  Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404).

Authors:  Barbara L Asselin; Meenakshi Devidas; Chenguang Wang; Jeanette Pullen; Michael J Borowitz; Robert Hutchison; Steven E Lipshultz; Bruce M Camitta
Journal:  Blood       Date:  2011-04-07       Impact factor: 22.113

Review 4.  Contribution of immunophenotypic and genotypic analyses to the diagnosis of acute leukemia.

Authors:  R Stasi; C G Taylor; A Venditti; G Del Poeta; G Aronica; C Bastianelli; M D Simone; F Buccisano; M C Cox; A Bruno
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.